Arthur A. Levin - Mar 12, 2024 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
Director
Signature
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Stock symbol
RNA
Transactions as of
Mar 12, 2024
Transactions value $
-$578,017
Form type
4
Date filed
3/12/2024, 08:41 PM
Previous filing
Jan 23, 2024
Next filing
Mar 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Options Exercise $31K +25K +143.09% $1.24 42.5K Mar 12, 2024 Direct F1
transaction RNA Common Stock Sale -$551K -25K -58.86% $22.04 17.5K Mar 12, 2024 Direct F1, F2
transaction RNA Common Stock Sale -$58.1K -2.64K -15.12% $22.00 14.8K Mar 12, 2024 Direct F3
holding RNA Common Stock 274K Mar 12, 2024 By family trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -25K -36.59% $0.00 43.3K Mar 12, 2024 Common Stock 25K $1.24 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes the following securities previously acquired by the Reporting Person: (i) 16,141 restricted stock units (RSUs) under the Issuer's 2020 Incentive Award Plan and (ii) 1,330 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan.
F2 This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.23. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Includes the following securities previously acquired by the Reporting Person: (i) 13,500 RSUs under the Issuer's 2020 Incentive Award Plan and (ii) 1,330 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan.
F4 All unexercised shares subject to the option are fully vested and exercisable as of the date hereof.